OR WAIT null SECS
December 17, 2025
Video
Sohail discusses the promising results from this retrospective cohort study which aims to put longstanding concerns about worsening infection to bed.
December 15, 2025
Article
FibroGen’s oral HIF-PH inhibitor showed improved transfusion independence in high–high-transfusion-burden MDS patients in a post hoc phase 3 MATTERHORN analysis.
December 10, 2025
Zackon discusses a retrospective 20-year analysis, which implies an easier-to-achieve hemoglobin target in myelodysplastic syndrome treatment.
December 08, 2025
The approval of Ayrmid’s omidubicel-onlv makes it the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia.
October 28, 2025
GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.
August 25, 2025
If approved, the investigative therapy could provide a frontline treatment for patients with SAA who do not have matched sibling donors for cell transplantation.
August 12, 2025
The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.
July 03, 2025
Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.
July 02, 2025
A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.
July 01, 2025
The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.
